Hemostatic effects of low-dose protamine following cardiopulmonary bypass

American Journal of Hematology

Volumn 64, Issue 2, 2000, Pages 112-115

  Miyashita, Tetsuya ^a,b   Nakajima, Toshito ^a   Hayashi, Yukio ^a   Kuro, Masakazu ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Cardiopulmonary bypass; Hemostasis; Platelet count; Platelet factor 4; Protamine

Indexed keywords

HEPARIN; PROTAMINE SULFATE; THROMBOCYTE FACTOR 4;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HEMOSTASIS; HEPARINIZATION; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT;

AGED; BLOOD CELL COUNT; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CORONARY ARTERY BYPASS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; PLATELET FACTOR 4; POSTOPERATIVE CARE; PROSPECTIVE STUDIES; PROTAMINES;

EID: 0034029186     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(200006)64:2<112::AID-AJH7>3.0.CO;2-N     Document Type: Article

References (22)

1. Frater RWM, Oka Y, Hong Y, et al. Protamine-induced circulatory change. J Thorac Cardiovasc Surg 1984;87:687-692.
2. Shapira N, Schaff HV, Piehler JM, et al. Cardiovascular effects of protamine sulfate in man. J Thorac Cardiovasc Surg 1982;84:505-514.
3. Horrow JC. Protamine: a review of its toxicity. Anesth Analg 1985; 64:348-361.
4. Friedenberg WR, Myers WO, Plotka ED, et al. Platelet dysfunction associated with cardiopulmonary bypass. Ann Thorac Surg 1978;25: 298-305.
5. Hird RB, Spinale FG, Hewett KW, et al. The direct effects of protamine sulfate on myocyte contractile processes. J Thorac Cardiovasc Surg 1994;108:1100-1114.
6. Kirklin JK, Chenoweth DE, Naftel DC, et al. Effects of protamine administration after cardiopulmonary bypass on complement, blood elements, and the haemodynamic state. Ann Thorac Surg 1986;41: 193-199.
7. Bernabei A, Gikakis N, Maione TE, et al. Reversal of heparin anticoagulation by recombinant platelet factor 4 and protamine sulfate in baboons during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1995;109:765-771.
8. Levy JH, Cormack JG, Morales A. Heparin neutralization by recombinant platelet factor 4 and protamine. Anesth Analg 1995;81:35-37.
9. Esposito RA, Culliford AT, Colvin SB, et al. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983;85:174-185.
10. Bull BS, Huse WM, Brauer FS, et al. Heparin therapy during extracorporeal circulation. J Thorac Cardiovasc Surg 1975;69:685-689.
11. Wright SJ, Murray WB, Hampton WA, et al. Calculating the protamine-heparin reversal ratio: a pilot study investigating a new method. J Cardiothorac Vasc Anesth 1993;7:416-421.
12. Gravlee GP, Case LD, Angert KC, et al. Variability of the activated coagulation time. Anesth Analg 1988;67:469-472.
13. Bode AP, Castellani WI, Hodges ED, et al. The effect of lysed platelet on neutralization of heparin in vitro with protamine as measured by the activated coagulation time (ACT). Thromb Haemost 1991;213-217.
14. Hill AG, Groom RC, Mario JA, et al. More precise heparin and protamine management during cardiopulmonary bypass. Proc Am Cardiovasc Perfusion 1988;85-89.
15. Despotis GJ, Summerfield AL, Joist JH, et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994;108:1076-1082.
16. Martin P, Horkay F, Gupta NK, et al. Heparin rebound phenomenon: much ado about nothing? Blood Coagulation Fibrinolysis 1992;3:187-191.
17. Baugh RF, Deemar KA, Zimmermann JJ. Heparinase in the activated clotting time assay: monitoring heparin-independent alterations in coagulation function. Cardiovasc Anesth 1992;74:201-205.
18. rd edition. Philadelphia: WB Saunders; 1993. p. 951-994.
19. Bjoraker DG, Ketcham TR. In vivo platelet response to clinical protamine sulfate infusion (abstract). Anesthesiology 1982;57:A-7.
20. Velders AJ, Wildevuur RH. Platelet damage by protamine and the protective effect of prostacyclin: an experimental study in dogs. Ann Thorac Surg 1986;42:168-171.
21. Zucker MB, Katz IR. Platelet factor 4: production, structure, and physiologic and immunologic action. Proc Soc Exp Biol Med 1991; 198:693-702.
22. Machi J, Sigel B, Feinberg H. Protamine-induced platelet aggregation and clotting investigated by ultrasound. Hemostasis 1987;17:226-234.